Intravitreal Bevacizumab for Adult-Onset Vitelliform Dystrophy: A Case Report

Montero, J A; Ruiz-Moreno, José M.; Vega, Concepción de la

doi:10.1177/112067210701700620

Cited by 28 publications

(16 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Parodi et al [5] studied a series of patients who were treated with a course of intravitreal bevacizumab for a period of more than 2 years and managed to document significant and sustainable improvement in terms of both BCVA and retinal thickness. That study added further data to earlier reports of an advantageous effect of bevacizumab in PD-associated CNVM [6]. Furthermore, Gallego-Pinazo et al [7] very recently published a series of female patients diagnosed with adult-onset foveomacullar vitelliform dystrophy-related CNVM in whom short-term promising results regarding BCVA were documented.…”

Section: Discussionsupporting

confidence: 58%

Intravitreal Ranibizumab in the Treatment of Butterfly-Shaped Pattern Dystrophy Associated with Choroidal Neovascularization: A Case Report

Empeslidis

Vardarinos

Deane

et al. 2012

Case Rep Ophthalmol

View full text Add to dashboard Cite

Purpose: To present and document the effectiveness of intravitreal ranibizumab in the treatment of patients with choroidal neovascularization due to butterfly-shaped pattern dystrophy (PD) of the macula. Methods: Three intravitreal ranibizumab injections of 0.5 mg/0.05 ml in monthly intervals were given to a patient with a previously diagnosed butterfly-shaped PD who subsequently developed subfoveal choroidal neovascularization on the right eye. The patient had previously received a combination of verteporfin/photodynamic therapy for a juxtafoveal choroidal neovascular membrane on the left eye. Results: At the end of the treatment course, there was significant improvement of the patient’s vision and the appearance of the macula on optic coherence tomography and fluorescein angiography. Best-corrected visual acuity improved from 6/12 to 6/6 and retinal thickness at the macula decreased from 323 to 247 µm. No subretinal fluid remained. The patient is clinically stable over a 12-month follow-up period. Conclusions: Intravitreal ranibizumab seems to be an effective and safe option for the treatment of subfoveal choroidal neovascularization in patients with butterfly-shaped PD.

show abstract

Section: Discussionsupporting

confidence: 58%

Intravitreal Ranibizumab in the Treatment of Butterfly-Shaped Pattern Dystrophy Associated with Choroidal Neovascularization: A Case Report

Empeslidis

Vardarinos

Deane

et al. 2012

Case Rep Ophthalmol

View full text Add to dashboard Cite

show abstract

“…The reason why ranibizumab and bevacizumab [3,4] have been shown to be effective in AOFVD is uncertain. Further long-term studies are warranted to confirm this hypothesis and to assess the time and frequency of recurrences.…”

Section: Discussionmentioning

confidence: 98%

“…AOVFD is often confused with other maculopathies, mainly age-related macular degeneration [2]. Although no treatment has been proved effective in improving AOFVD visual outcomes, recent publications have suggested a possible role for anti-vascular endothelial growth factor (VEGF) therapy [3,4].…”

Section: Introductionmentioning

confidence: 99%

Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy

Gallego-Pinazo

Dolz-Marco

Pardo-López

et al. 2010

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…These include studies with a short follow-up for CNV secondary to Best disease, 81 vitelliform degeneration, 82 choroidal oesteoma, 83 and pseudotumour cerebri. 84 …”

Section: Other Causes Of Cnvmentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies.

show abstract

Intravitreal Bevacizumab for Adult-Onset Vitelliform Dystrophy: A Case Report

Abstract: Intravitreal bevacizumab showed a morphologic improvement and stable VA in a patient with AFVD. Further case series are required to confirm this observation.

Cited by 28 publications

References 4 publications

Intravitreal Ranibizumab in the Treatment of Butterfly-Shaped Pattern Dystrophy Associated with Choroidal Neovascularization: A Case Report

Intravitreal Ranibizumab in the Treatment of Butterfly-Shaped Pattern Dystrophy Associated with Choroidal Neovascularization: A Case Report

Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Contact Info

Product

Resources

About